NeOnc Technologies Wins California Investment Forum’s Breakthrough Medical Technology Achievement Award

Clinical-Stage Biopharmaceutical Company Receives Recognition of Novel Therapeutics and Drug Delivery Methods for Treating Brain and Central Nervous System Diseases

LOS ANGELES, May 15, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage biopharmaceutical company, has received the Breakthrough Medical Technology Achievement Award from the California Investment Forum (CIF) for its innovations in medical technology related to the treatment of brain and central nervous system diseases.

The award was presented to NeOnc by California State Treasurer, Fiona Ma, at the 2024 CIF Innovation Awards ceremony held last Friday in Anaheim, California. The 2024 CIF Innovation Awards recognizes ‘groundbreaking companies for leading the charge towards an innovative future.’

NeOnc was selected from among the several leading companies from around the world and across multiple sectors who participated in the annual investment forum held last week. The California Investment Forum provides companies with direct access to a network of investors and partners dedicated to fostering innovative solutions.

“We are honored to be recognized by the CIF committee members,” stated NeOnc founder, CEO and chief science officer, Thomas Chen, M.D. Ph.D. “The award helps to bring important attention to our NEO drug development platform which has the potential to elevate the standard of care for primary brain tumors and other cancers that can spread to the brain.”

Dr. Chen was joined at the awards ceremony by NeOnc’s executive chairman, Amir Heshmatpour, CFO Keithly Garnett, and COO Patrick Walters. Earlier in the day, they presented to the conference NeOnc’s patented intranasal delivery system—a technology designed to allow therapeutics to bypass the blood-brain barrier via the olfactory or trigeminal nerves and thereby potentially enhancing treatment efficacy and ease of application.

Amir Heshmatpour commented: “We are thrilled that NeOnc Technologies has been recognized by Treasurer Ma and the distinguished guests of the California Investment Forum for our drug delivery technology.”

Secured under exclusive worldwide rights from the University of Southern California (USC), NeOnc’s intellectual property portfolio includes 135 U.S. and international patents issued and pending.

Dr. Chen is a widely respected neurosurgery professor and medical expert who was recognized last year for his achievements by the American Health Council with its Best in Medicine Award.

About California Investment Forum